Pasithea receives FDA orphan drug designation for ALS treatment PAS-004 Jun 2, 2026 07:02AM
Pasithea Therapeutics receives FDA rare pediatric disease designation for PAS-004 Apr 20, 2026 07:01AM
Pasithea receives FDA fast track designation for NF1 tumor treatment Apr 1, 2026 07:03AM
Pasithea Therapeutics provides updated clinical trial timelines Jan 13, 2026 07:03AM
H.C. Wainwright Starts Pasithea Therapeutics Corp. (KTTA) at Buy Dec 8, 2025 06:22AM


Nov 25, 2025 07:00AM Pasithea receives $1 million ALS Association grant for PAS-004 trial
Jun 2, 2025 08:06AM Pasithea Therapeutics (KTTA) Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004
May 20, 2025 07:07AM Pasithea Therapeutics (KTTA) Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
May 6, 2025 07:03AM Pasithea Therapeutics (KTTA) Reports Positive Pharmacodynamic Results from Phase 1 Trial of PAS-004
Apr 10, 2025 07:02AM Pasithea Therapeutics (KTTA) Announces Positive Safety Review Committee Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004
Feb 5, 2025 06:59AM Pasithea Therapeutics (KTTA) Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004
Nov 20, 2024 07:03AM Pasithea Therapeutics (KTTA) Announces Positive Safety Review Committee Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Sep 27, 2024 06:02AM Pasithea Therapeutics (KTTA) Prices 1.22M Share Offering at $4.10/sh
Sep 26, 2024 07:02AM Pasithea Therapeutics (KTTA) Reports Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from Phase 1 Trial of PAS-004
Sep 9, 2024 08:01AM Pasithea Therapeutics (KTTA) Announces Successful Completion of PAS-004 Chronic Toxicity Studies